First Time Loading...

Evaxion Biotech A/S
NASDAQ:EVAX

Watchlist Manager
Evaxion Biotech A/S Logo
Evaxion Biotech A/S
NASDAQ:EVAX
Watchlist
Price: 4.2071 USD 2.11%
Updated: Apr 26, 2024

Intrinsic Value

Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. [ Read More ]

The intrinsic value of one EVAX stock under the Base Case scenario is 172.2855 USD. Compared to the current market price of 4.2071 USD, Evaxion Biotech A/S is Undervalued by 98%.

Key Points:
EVAX Intrinsic Value
Base Case
172.2855 USD
Undervaluation 98%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

Beta
Ask me anything about
Evaxion Biotech A/S

Provide an overview of the primary business activities
of Evaxion Biotech A/S.

What unique competitive advantages
does Evaxion Biotech A/S hold over its rivals?

What risks and challenges
does Evaxion Biotech A/S face in the near future?

Summarize the latest earnings call
of Evaxion Biotech A/S.

Show all valuation multiples
for Evaxion Biotech A/S.

Provide P/S
for Evaxion Biotech A/S.

Provide P/E
for Evaxion Biotech A/S.

Provide P/OCF
for Evaxion Biotech A/S.

Provide P/FCFE
for Evaxion Biotech A/S.

Provide P/B
for Evaxion Biotech A/S.

Provide EV/S
for Evaxion Biotech A/S.

Provide EV/GP
for Evaxion Biotech A/S.

Provide EV/EBITDA
for Evaxion Biotech A/S.

Provide EV/EBIT
for Evaxion Biotech A/S.

Provide EV/OCF
for Evaxion Biotech A/S.

Provide EV/FCFF
for Evaxion Biotech A/S.

Provide EV/IC
for Evaxion Biotech A/S.

Show me price targets
for Evaxion Biotech A/S made by professional analysts.

What are the Revenue projections
for Evaxion Biotech A/S?

How accurate were the past Revenue estimates
for Evaxion Biotech A/S?

What are the Net Income projections
for Evaxion Biotech A/S?

How accurate were the past Net Income estimates
for Evaxion Biotech A/S?

What are the EPS projections
for Evaxion Biotech A/S?

How accurate were the past EPS estimates
for Evaxion Biotech A/S?

What are the EBIT projections
for Evaxion Biotech A/S?

How accurate were the past EBIT estimates
for Evaxion Biotech A/S?

Compare the revenue forecasts
for Evaxion Biotech A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Evaxion Biotech A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Evaxion Biotech A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Evaxion Biotech A/S compared to its peers.

Compare the P/E ratios
of Evaxion Biotech A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Evaxion Biotech A/S with its peers.

Analyze the financial leverage
of Evaxion Biotech A/S compared to its main competitors.

Show all profitability ratios
for Evaxion Biotech A/S.

Provide ROE
for Evaxion Biotech A/S.

Provide ROA
for Evaxion Biotech A/S.

Provide ROIC
for Evaxion Biotech A/S.

Provide ROCE
for Evaxion Biotech A/S.

Provide Gross Margin
for Evaxion Biotech A/S.

Provide Operating Margin
for Evaxion Biotech A/S.

Provide Net Margin
for Evaxion Biotech A/S.

Provide FCF Margin
for Evaxion Biotech A/S.

Show all solvency ratios
for Evaxion Biotech A/S.

Provide D/E Ratio
for Evaxion Biotech A/S.

Provide D/A Ratio
for Evaxion Biotech A/S.

Provide Interest Coverage Ratio
for Evaxion Biotech A/S.

Provide Altman Z-Score Ratio
for Evaxion Biotech A/S.

Provide Quick Ratio
for Evaxion Biotech A/S.

Provide Current Ratio
for Evaxion Biotech A/S.

Provide Cash Ratio
for Evaxion Biotech A/S.

What is the historical Revenue growth
over the last 5 years for Evaxion Biotech A/S?

What is the historical Net Income growth
over the last 5 years for Evaxion Biotech A/S?

What is the current Free Cash Flow
of Evaxion Biotech A/S?

Discuss the annual earnings per share (EPS)
trend over the past five years for Evaxion Biotech A/S.

Financials

Balance Sheet Decomposition
Evaxion Biotech A/S

Current Assets 8.4m
Cash & Short-Term Investments 5.6m
Receivables 815k
Other Current Assets 2m
Non-Current Assets 4.5m
PP&E 4.3m
Other Non-Current Assets 196k
Current Liabilities 7.1m
Accounts Payable 2.7m
Other Current Liabilities 4.4m
Non-Current Liabilities 10.5m
Long-Term Debt 10.4m
Other Non-Current Liabilities 149k
Efficiency

Earnings Waterfall
Evaxion Biotech A/S

Revenue
73k USD
Operating Expenses
-22.3m USD
Operating Income
-22.2m USD
Other Expenses
72k USD
Net Income
-22.1m USD

Free Cash Flow Analysis
Evaxion Biotech A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

EVAX Profitability Score
Profitability Due Diligence

Evaxion Biotech A/S's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

19/100
Profitability
Score

Evaxion Biotech A/S's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

EVAX Solvency Score
Solvency Due Diligence

Evaxion Biotech A/S's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
34/100
Solvency
Score

Evaxion Biotech A/S's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EVAX Price Targets Summary
Evaxion Biotech A/S

Wall Street analysts forecast EVAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EVAX is 11.985 USD with a low forecast of 7.07 USD and a high forecast of 18.9 USD.

Lowest
Price Target
7.07 USD
68% Upside
Average
Price Target
11.985 USD
185% Upside
Highest
Price Target
18.9 USD
349% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

EVAX Price
Evaxion Biotech A/S

1M 1M
+34%
6M 6M
+413%
1Y 1Y
+229%
3Y 3Y
-43%
5Y 5Y
-58%
10Y 10Y
-58%
Annual Price Range
4.2071
52w Low
0.48
52w High
10.65
Price Metrics
Average Annual Return -58.11%
Standard Deviation of Annual Returns 5.52%
Max Drawdown -96%
Shares Statistics
Market Capitalization 20.2m USD
Shares Outstanding 4 811 560
Percentage of Shares Shorted 1.18%

EVAX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Evaxion Biotech A/S Logo
Evaxion Biotech A/S

Country

Denmark

Industry

Biotechnology

Market Cap

20.2m USD

Dividend Yield

0%

Description

Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Contact

COPENHAGEN
Bredgade 34E, Copenhagen K
http://www.evaxion-biotech.com/

IPO

2021-02-05

Employees

61

Officers

Chief Executive Officer
Mr. Christian Kanstrup M.Sc.
Co-Founder and Chief AI & Culture Officer
Mr. Andreas Holm Mattsson
CFO & COO
Mr. Jesper Nyegaard Nissen M.Sc.
Co-Founder, VP of Business & Director
Dr. Niels Iversen Moller M.D.
Chief Scientific Officer
Dr. Birgitte Rono Ph.D.
Head of Business Development & Member of Advisory Board
Dr. Jürgen Langhärig EMBA, Ph.D.

See Also

Discover More